Literature DB >> 27421483

Complex Negative Regulation of TLR9 by Multiple Proteolytic Cleavage Events.

Siddhartha S Sinha1, Jody Cameron1, James C Brooks2, Cynthia A Leifer3.   

Abstract

TLR9 is an innate immune receptor important for recognizing DNA of host and foreign origin. A mechanism proposed to prevent excessive response to host DNA is the requirement for proteolytic cleavage of TLR9 in endosomes to generate a mature form of the receptor (TLR9(471-1032)). We previously described another cleavage event in the juxtamembrane region of the ectodomain that generated a dominant-negative form of TLR9. Thus, there are at least two independent cleavage events that regulate TLR9. In this study, we investigated whether an N-terminal fragment of TLR9 could be responsible for regulation of the mature or negative-regulatory form. We show that TLR9(471-1032), corresponding to the proteolytically cleaved form, does not function on its own. Furthermore, activity is not rescued by coexpression of the N-terminal fragment (TLR9(1-440)), inclusion of the hinge region (TLR9(441-1032)), or overexpression of UNC93B1, the last of which is critical for trafficking and cleavage of TLR9. TLR9(1-440) coimmunoprecipitates with full-length TLR9 and TLR9(471-1032) but does not rescue the native glycosylation pattern; thus, inappropriate trafficking likely explains why TLR9(471-1032) is nonfunctional. Lastly, we show that TLR9(471-1032) is also a dominant-negative regulator of TLR9 signaling. Together, these data provide a new perspective on the complexity of TLR9 regulation by proteolytic cleavage and offer potential ways to inhibit activity through this receptor, which may dampen autoimmune inflammation.
Copyright © 2016 by The American Association of Immunologists, Inc.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27421483      PMCID: PMC4976034          DOI: 10.4049/jimmunol.1502357

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  35 in total

1.  A Toll-like receptor recognizes bacterial DNA.

Authors:  H Hemmi; O Takeuchi; T Kawai; T Kaisho; S Sato; H Sanjo; M Matsumoto; K Hoshino; H Wagner; K Takeda; S Akira
Journal:  Nature       Date:  2000-12-07       Impact factor: 49.962

2.  Antimicrobial peptides inhibit polyinosinic-polycytidylic acid-induced immune responses.

Authors:  Maroof Hasan; Catarina Ruksznis; Yan Wang; Cynthia Anne Leifer
Journal:  J Immunol       Date:  2011-11-02       Impact factor: 5.422

3.  The Unc93b1 mutation 3d disrupts exogenous antigen presentation and signaling via Toll-like receptors 3, 7 and 9.

Authors:  Koichi Tabeta; Kasper Hoebe; Edith M Janssen; Xin Du; Philippe Georgel; Karine Crozat; Suzanne Mudd; Navjiwan Mann; Sosathya Sovath; Jason Goode; Louis Shamel; Anat A Herskovits; Daniel A Portnoy; Michael Cooke; Lisa M Tarantino; Tim Wiltshire; Benjamin E Steinberg; Sergio Grinstein; Bruce Beutler
Journal:  Nat Immunol       Date:  2006-01-15       Impact factor: 25.606

4.  Cutting edge: a TLR9 cytoplasmic tyrosine motif is selectively required for proinflammatory cytokine production.

Authors:  Annapoorani Chockalingam; William Alfred Rose; Maroof Hasan; Chia-Hsin Ju; Cynthia Anne Leifer
Journal:  J Immunol       Date:  2011-12-14       Impact factor: 5.422

5.  Proteolytic cleavage in an endolysosomal compartment is required for activation of Toll-like receptor 9.

Authors:  Boyoun Park; Melanie M Brinkmann; Eric Spooner; Clarissa C Lee; You-Me Kim; Hidde L Ploegh
Journal:  Nat Immunol       Date:  2008-10-19       Impact factor: 25.606

6.  TLR9 signals after translocating from the ER to CpG DNA in the lysosome.

Authors:  Eicke Latz; Annett Schoenemeyer; Alberto Visintin; Katherine A Fitzgerald; Brian G Monks; Cathrine F Knetter; Egil Lien; Nadra J Nilsen; Terje Espevik; Douglas T Golenbock
Journal:  Nat Immunol       Date:  2004-01-11       Impact factor: 25.606

7.  Folding of Toll-like receptors by the HSP90 paralogue gp96 requires a substrate-specific cochaperone.

Authors:  Bei Liu; Yi Yang; Zhijuan Qiu; Matthew Staron; Feng Hong; Yi Li; Shuang Wu; Yunfeng Li; Bing Hao; Robert Bona; David Han; Zihai Li
Journal:  Nat Commun       Date:  2010-09-21       Impact factor: 14.919

8.  Nucleic acid recognition by Toll-like receptors is coupled to stepwise processing by cathepsins and asparagine endopeptidase.

Authors:  Sarah E Ewald; Alex Engel; Jiyoun Lee; Miqi Wang; Matthew Bogyo; Gregory M Barton
Journal:  J Exp Med       Date:  2011-03-14       Impact factor: 14.307

9.  The ectodomain of Toll-like receptor 9 is cleaved to generate a functional receptor.

Authors:  Sarah E Ewald; Bettina L Lee; Laura Lau; Katherine E Wickliffe; Guo-Ping Shi; Harold A Chapman; Gregory M Barton
Journal:  Nature       Date:  2008-09-28       Impact factor: 49.962

10.  A protein associated with Toll-like receptor (TLR) 4 (PRAT4A) is required for TLR-dependent immune responses.

Authors:  Koichiro Takahashi; Takuma Shibata; Sachiko Akashi-Takamura; Takashi Kiyokawa; Yasutaka Wakabayashi; Natsuko Tanimura; Toshihiko Kobayashi; Fumi Matsumoto; Ryutaro Fukui; Taku Kouro; Yoshinori Nagai; Kiyoshi Takatsu; Shin-ichiroh Saitoh; Kensuke Miyake
Journal:  J Exp Med       Date:  2007-11-06       Impact factor: 14.307

View more
  11 in total

1.  TLR-7 Stress Signaling in Differentiating and Mature Eosinophils Is Mediated by the Prolyl Isomerase Pin1.

Authors:  Zhong-Jian Shen; Jie Hu; Venkatesh Kashi; Yury A Bochkov; James E Gern; James S Malter
Journal:  J Immunol       Date:  2018-11-05       Impact factor: 5.422

Review 2.  Nucleic acid-sensing TLRs: trafficking and regulation.

Authors:  Olivia Majer; Bo Liu; Gregory M Barton
Journal:  Curr Opin Immunol       Date:  2016-11-28       Impact factor: 7.486

3.  Toll-like receptor signaling in macrophages is regulated by extracellular substrate stiffness and Rho-associated coiled-coil kinase (ROCK1/2).

Authors:  Erika Gruber; Christa Heyward; Jody Cameron; Cynthia Leifer
Journal:  Int Immunol       Date:  2018-05-24       Impact factor: 5.071

4.  Toll-like receptor expression and function differ between splenic marginal zone B cell lymphoma and splenic diffuse red pulp B cell lymphoma.

Authors:  Aurélie Verney; Alexandra Traverse-Glehen; Evelyne Callet-Bauchu; Laurent Jallades; Jean-Pierre Magaud; Gilles Salles; Laurent Genestier; Lucile Baseggio
Journal:  Oncotarget       Date:  2018-05-04

5.  TLR9 signaling activation at different stages in colorectal cancer and NF-kappaB expression.

Authors:  Caixia Gao; Tiankui Qiao; Bin Zhang; Sujuan Yuan; Xibing Zhuang; Youjun Luo
Journal:  Onco Targets Ther       Date:  2018-09-18       Impact factor: 4.147

6.  Tyrosine 870 of TLR9 is critical for receptor maturation rather than phosphorylation-dependent ligand-induced signaling.

Authors:  Chhanda Biswas; Sheila Rao; Katharine Slade; David Hyman; Devin Dersh; Adriana R Mantegazza; Philip W Zoltick; Michael S Marks; Yair Argon; Edward M Behrens
Journal:  PLoS One       Date:  2018-07-19       Impact factor: 3.240

Review 7.  Below the surface: The inner lives of TLR4 and TLR9.

Authors:  Laura Marongiu; Laura Gornati; Irene Artuso; Ivan Zanoni; Francesca Granucci
Journal:  J Leukoc Biol       Date:  2019-03-22       Impact factor: 4.962

8.  Immunomodulatory nanogels overcome restricted immunity in a murine model of gut microbiome-mediated metabolic syndrome.

Authors:  Matthew J Mosquera; Sungwoong Kim; Hao Zhou; Tina T Jing; Marysol Luna; Jason D Guss; Pooja Reddy; Kristine Lai; Cynthia A Leifer; Ilana L Brito; Christopher J Hernandez; Ankur Singh
Journal:  Sci Adv       Date:  2019-03-27       Impact factor: 14.136

9.  B Lymphocytes as Targets of the Immunomodulatory Properties of Human Amniotic Mesenchymal Stromal Cells.

Authors:  Marta Magatti; Alice Masserdotti; Patrizia Bonassi Signoroni; Elsa Vertua; Francesca Romana Stefani; Antonietta Rosa Silini; Ornella Parolini
Journal:  Front Immunol       Date:  2020-06-09       Impact factor: 7.561

10.  Molecular regulation of TLR signaling in health and disease: mechano-regulation of macrophages and TLR signaling.

Authors:  Erika J Gruber; Cynthia A Leifer
Journal:  Innate Immun       Date:  2020-01       Impact factor: 2.680

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.